Demographics |
Demographics |
Demographics |
Demographics |
Participants N (%) |
35 |
17 |
52 |
Female sex N (%) |
15 (42.9) |
11 (64.7) |
26 (50.0) |
Median age of symptom onset in years (IQR) |
7.0 (3.4-13.0) |
10.0
(8.0-13.0) |
10.0 (5.0-13.0) |
Median age at study enrolment in years (IQR) |
7.4 (5.8-14.4) |
11.9
(8.7-14.8) |
11.8 (6.3-14.5) |
Median disease duration in years (IQR) |
0.8 (0.4-1.6) |
1.0 (0.7-2.2) |
0.8 (0.4-2.0) |
Median baseline UCT score (IQR) |
8.0 (7.0-12.0) |
10.0 (6.0-12.0) |
8.0
(7.0-12.0) |
Median baseline CDLQI score (IQR) |
4.0 (1.0-8.0) |
5.0 (4.0-6.0) |
5.0
(2.0-7.0) |
Well-Controlled Disease (CDLQI≤5) |
20 (57.1) |
10 (58.8) |
30
(57.7) |
Comorbidities |
Comorbidities |
Comorbidities |
Comorbidities |
Asthma N (%) |
3 (8.6) |
3 (17.6) |
6 (11.5) |
Atopic dermatitis N (%) |
4 (11.4) |
5 (29.4) |
9 (17.3) |
Allergic rhinitis N (%) |
5 (14.3) |
3 (18.8) |
8 (15.4) |
Food allergies N (%) |
4 (11.4) |
1 (5.8) |
5 (9.6) |
Insect sting allergy N (%) |
1 (2.9) |
0 (0) |
1 (1.9) |
Autoimmune disease N (%) |
1 (2.9) |
1 (5.8) |
2 (3.8) |
Celiac disease N (%) |
0 (0) |
1 (5.8) |
1 (1.9) |
Crohn’s disease N (%) |
1 (2.9) |
0 (0) |
1 (1.9) |
Autoinflammatory disease N (%) |
0 (0) |
0 (0) |
0 (0) |
Management |
Management |
Management |
Management |
Second generation H1-antihistamines N (%) |
14 (40.0) |
10 (58.8) |
24
(46.2) |
Short-course oral corticosteroids N (%) |
0 (0.0) |
0 (0.0) |
0
(0.0) |
Omalizumab N (%) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
No medication N (%) |
21 (60.0) |
7 (41.2) |
28 (53.8) |